KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $76,000.

  • Nektar Therapeutics' Gains from Investment Securities rose 19.47% to -$7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76,000, marking a year-over-year decrease of 97.14%. This contributed to the annual value of $76,000 for FY2024, which is 97.14% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Gains from Investment Securities of $76,000 as of FY2024, which was down 97.14% from $2.7 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Gains from Investment Securities ranged from a high of $3.3 million in FY2022 and a low of $76,000 during FY2024.
  • Its 3-year average for Gains from Investment Securities is $2.0 million, with a median of $2.7 million in 2023.
  • As far as peak fluctuations go, Nektar Therapeutics' Gains from Investment Securities soared by 214.66% in 2022, and later crashed by 97.14% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Gains from Investment Securities (Yearly) stood at $2.1 million in 2020, then plummeted by 50.45% to $1.1 million in 2021, then soared by 214.66% to $3.3 million in 2022, then declined by 20.14% to $2.7 million in 2023, then tumbled by 97.14% to $76,000 in 2024.